Concerns around the extensive use of mesalazine for ulcerative colitis and continuous treatment with biologics for Crohn’s disease have been referred to the next meeting of PBAC. A Drug Utilisation Sub-Committee (DUSC) charged with investigating the cost-effectiveness of medicines used in IBD found mesalazine was the most commonly prescribed medicine and its use was increasing. ...
Extensive and extended use of IBD medicines flagged
By Mardi Chapman
14 Jul 2017